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Abstract
Background: Candidemia is a significant cause of morbidity and mortality in hospitalized patients, particularly in Asia.
Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is
known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different.
Methods: An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several
Asian countries. Treatment was initiated with intravenous anidulafungin, given for at least 5 days, with the option to
complete treatment with oral voriconazole. The primary endpoint was global (clinical and microbiological) response,
and the primary analysis was the proportion of patients in the modified intent-to-treat population with successful
global response at the end of therapy. Secondary analyses included proportion with successful global response in
clinically relevant patient subgroups. The safety and tolerability profile of anidulafungin and voriconazole in this
population was also investigated.
Results: Forty-three patients were studied, including 42 in the modified intent-to-treat population. Eighteen patients
were > 65 years, the largest age subgroup, and 21 had central venous catheters. The most common Candida species
causing infection were C. tropicalis (n = 18) and C. albicans (n = 10). In the primary analysis, 73.8% had a successful
global response at end of therapy. Success rates in subgroups were: 72.2% for C. tropicalis and 71.4% for C. albicans
infection, 58.8% for patients > 65 years, and 81.0% for patients with central venous catheters. Safety and tolerability
were comparable with the known profiles for anidulafungin (and voriconazole).
Conclusions: Although the epidemiology of Candida infections was different in this open-label study, the efficacy of
anidulafungin in Asian patients with documented candidemia was consistent with previous studies in Western
populations. No new safety concerns were identified.
Trial registration: www.clinicaltrials.gov identifier NCT00537329
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Background
Candida species are the main cause of invasive fungal
disease, affecting a wide variety of patient populations,
including critically ill patients, patients with hematological
malignancies, elderly hospitalized patients, solid-organ
transplant recipients, and adult diabetic patients [1].
C. albicans remains the most common pathogen causing
candidemia and invasive candidiasis (C/IC), both worldwide
[1,2] and in Asia [3], but other species are becoming
increasingly common [1,4-7]. Moreover, species distri-
bution and susceptibility to antifungal agents, show
considerable geographic variation [3]. Therefore, knowledge
of local epidemiology is important for the effective
management of candidemia.
Crude mortality rates associated with C/IC are substan-
tial, ranging from 30% to 81% according to recent reports
[2,4]. Mortality varies according to patient age, pre-existing
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comorbidities, and the causative Candida species; the
highest mortality rates are observed with C. krusei, followed
by C. tropicalis and C. glabrata [2,8].
Regional data for C/IC in Asia are scarce. A retrospective
review of admissions to a Korean intensive care unit
reported an incidence of candidemia of 9.1 cases per 1000
admissions, with a notably high crude mortality of 96%,
due to a high proportion of patients with malignancy [9].
Four centers in Taiwan reported crude mortality ranging
from 43.1% to 60.7% [10], and a tertiary care center in
North India reported a decrease in mortality rate from
72.2% to 47% over a 5-year period as awareness of disease
prevalence increased [11].
Fluconazole is the most commonly used candidemia
therapy, but susceptibility to fluconazole varies, both by
Candida species and by geographical region [3]. Thus,
other antifungal agents are also required that are more
effective than fluconazole against Candida, particularly
in regional populations where C. albicans is no longer
the most common species causing infection.
The echinocandin anidulafungin is an effective alternative
to fluconazole, demonstrating superiority to fluconazole for
the treatment of C/IC in a pivotal clinical trial by Reboli
et al. [12]. However, clinical studies of anidulafungin have
so far been conducted mostly in North America and
Europe, with few Asian patients studied [12-14]. Racial
groups may differ in terms of epidemiology, disease
presentation, drug tolerability, and response to treatment
[8,15-19]. Thus, assessment of potential clinically relevant
differences between Asian and Western populations treated
with anidulafungin is required. Moreover, the extended-
spectrum triazole voriconazole has been reported to have
greater in vitro activity against most Candida species
compared with fluconazole [3].
This study aimed primarily to evaluate the efficacy and
safety of intravenous (i.v.) anidulafungin for the treatment
of documented candidemia in a broad and diverse popula-
tion of Asian patients, with Acute Physiology and Chronic
Health Evaluation (APACHE II) scores ≤ 20. The activity
of anidulafungin was investigated across a range of pre-
defined patient subgroups. In addition, the relationship
between response to treatment and β-D glucan levels
was investigated. Step-down therapy to oral voriconazole
following at least 5 days of i.v. anidulafungin was permitted,
to investigate whether treatment success rates comparable
with fluconazole could be achieved [3], whilst providing




This was a prospective Phase III, 12-week, open-label,
multicenter, non-comparative study (January 2008 to
March 2009). The trial was performed in accordance
with the Declaration of Helsinki and International
Conference on Harmonisation Good Clinical Practice
guidelines; each center was also approved by the local
institutional review board (IRB) (please see Additional
file 1 for full details of the IRBs). Periodic monitoring
visits were performed by the study sponsor or approved
agents. Full ethical approval was obtained at each partici-
pating center, and all patients provided written informed
consent prior to screening. Patients could withdraw from
the trial at any time. The trial was registered on www.
clinicaltrials.gov under the identifier NCT00537329.
Patients
Patients were eligible for participation if they had at
least one blood culture positive for Candida species
(within 96 h of starting study treatment), and clinical
evidence of infection within 48 h prior to study enrollment.
They were required to be at least 18 years of age, of Asian
race, and to have an APACHE II score of ≤ 20. Patients
were excluded in the event of: suspected Candida
osteomyelitis, endocarditis, meningitis, endophthalmitis,
septic thrombophlebitis, or hepatosplenic candidiasis;
administration of > 48 h of systemic antifungal therapy
within 2 weeks before enrollment; previous history
of anidulafungin treatment; hypersensitivity to any
echinocandins or azole therapy; an estimated life ex-
pectancy of < 72 h; and pregnancy.
ITT population
The intent-to-treat (ITT) population comprised all patients
who received at least one dose of anidulafungin, and was
used for the safety analysis.
MITT population
The modified ITT (MITT) population comprised all
ITT patients with a confirmed diagnosis of candidemia
and was used for the efficacy analysis.
Per-protocol population
The per-protocol population comprised MITT patients
who were compliant with the study protocol, i.e. pa-
tients who received at least 5 days of i.v. anidulafungin
(unless deemed a treatment failure after three doses of
study medication); had an overall study drug compliance
(as measured by pill count) of ≥ 75% and ≤ 120% for
oral voriconazole; and did not receive any concomitant
systemic antifungal agents.
Study treatment
Patients received 200 mg i.v. anidulafungin as a single load-
ing dose on Day 1, followed by 100 mg i.v. anidulafungin
once daily thereafter for a minimum of 5 days. After 5 days,
patients were allowed to step down to 200 mg twice-daily
(BID) oral voriconazole (or 100 mg BID if body weight
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was < 40 kg). Criteria for step-down therapy were as
follows: negative blood culture for Candida species;
resolution or significant improvement of clinical signs/
symptoms of acute invasive fungal disease, and no clin-
ical evidence of invasive fungal disease, as assessed by
the investigator; absence of neutropenia (i.e. absolute
neutrophil count ≤ 500/mm3); hemodynamically stable;
patient was able to take oral medication and had a
functional gastrointestinal tract; and did not have any
contraindications (including contraindicated concomitant
medications) to voriconazole. If these conditions were not
fulfilled, the patient was continued on anidulafungin until
alternative systemic antifungal therapy was required.
Treatment with either anidulafungin only or anidulafungin
followed by voriconazole was continued as deemed appro-
priate by the investigator, up to a maximum of 42 days.
Concomitant systemic antifungal agents were not per-
mitted during the study, although topical antifungal agents
were allowed at the investigators’ discretion. All other
treatments (including antimicrobial and antiviral agents)
indicated for the primary illness and supportive medi-
cations were continued throughout the study.
Laboratory monitoring
Blood cultures were taken on Days 1–6, or until a negative
culture for Candida species was obtained. If the blood
culture remained positive on Day 6, a repeat blood culture
was carried out on Day 7 and then weekly thereafter,
until a negative result was reported. The presence of
Candida species was initially determined at local labora-
tories. Blood samples for the Fungitell β-D glucan assay
(Associates of Cape Cod, East Falmouth, MA, USA) were
analyzed by a single reference laboratory for the study
[20]. Batch samples, prepared by the local laboratory, were
sent to a central laboratory in each participating country
for confirmation of pathogen identification and suscepti-
bility testing to anidulafungin and voriconazole. Isolates
with an anidulafungin minimum inhibitory concentration
(MIC) of ≤ 2 μg/ml were considered susceptible, while those
with an MIC of > 2 μg/ml were considered non-susceptible
based on Pfaller et al. [21]. Voriconazole breakpoints
used were ≤ 1 μg/ml (susceptible), > 1 to 4 μg/ml
(susceptible dose-dependent), and > 4 μg/ml (resistant)
based on Pfaller et al. [22].
Efficacy endpoints
The primary endpoint of the study was the proportion
of patients in the MITT population with successful
global response at end of all treatment (EOT) on or before
Day 42. Global response was deemed successful if there
was both clinical success (defined as cure – resolution
of signs and symptoms of candidemia, or significant
improvement – incomplete but significant resolution of
signs and symptoms of candidemia) and microbiological
success (defined as eradication if follow-up culture result
is negative for Candida species, or presumed eradication
if follow-up blood cultures were not available, but the
clinical outcome was defined as success). Failure of
response was defined as no significant improvement in
signs and symptoms, death due to candidemia, or positive
follow-up blood culture result. Indeterminate response
included death not attributable to candidemia, or patient
lost to follow-up. Missing values for patients who withdrew
prematurely from the study with a documented failure were
imputed using the last observation carried forward (LOCF)
approach. To ensure consistency across studies of similar
design conducted globally, a decision was made post hoc to
include missing and indeterminate values as failures.
Secondary efficacy endpoints included: global response
rate and clinical and microbiological responses at the
end of i.v. anidulafungin treatment (EOIT), at 2 and
6 weeks follow-up visits after EOT and at the end of
12 weeks from baseline; time to death, mortality attributed
to candidemia and all-cause mortality. Global response
rates at EOT were assessed in pre-defined patient sub-
groups and in patients with risk factors for candidemia.
Pre-defined subgroups included neutropenic status
and Candida species isolated at baseline. Risk factors
for candidemia included central venous catheter, renal
insufficiency, post-surgery status, age ≥ 65 years, chemo-
therapy within the previous 3 months, and solid organ
transplantation.
Safety assessments
The safety and tolerability analyses of anidulafungin
were conducted throughout the study on the ITT
population. Safety assessments were measured using
adverse-event (AE) monitoring, clinical laboratory parame-
ters, fundoscopy, physical and neurological examination,
and vital-sign measurements.
All AEs and serious AEs were reported to the investigator
and noted in the case report form, using the Medical
Dictionary for Regulatory Activities coding system
(Version 12.0). The investigator was required to assess
the causality and severity of the AE.
Statistical analysis
It was planned to enroll 100 patients for this study,
assuming an overall response rate of 75%, the 95%
confidence interval (CI) for the percentage of patients
responding to treatment would range from 66.3% to
83.7%, allowing for 5% non-evaluability based on the
Reboli et al. study [12].
For the global, clinical, and microbiologic success rates in
the MITT population, a two-sided exact (Clopper-Pearson)
95% CI was calculated [23]. In addition, descriptive
summaries were provided for all secondary efficacy
endpoints. Continuous outcomes were summarized by
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the number of observations, mean, standard deviation
(SD), median, and range. Categorical outcomes were
summarized as count and percentage in each category.
Results
Study population
Participants were recruited from 13 study centers across
Asia. Due to difficult enrollment, the study was closed
before target enrollment could be met. Forty-three patients
were studied; however, one patient did not have a con-
firmed documented diagnosis of candidemia and therefore
only 42 patients were included in the MITT population.
Eighteen patients were > 65 years, the largest age subgroup.
Twenty-one patients had a central venous catheter up to
1 month before baseline (Figure 1, Table 1). At the start of
the study, 11 patients had hepatobiliary disorders, 15 had
renal and urinary disorders, and 7 patients were receiving
chemotherapy.
The most common Candida species isolated was C.
tropicalis (41.9%, 18/43 patients), followed by C. albicans
(32.6%, 14/43 patients). Forty-one of the 43 isolates were
tested for susceptibility to study treatment. Susceptibility to
anidulafungin was 97.6% (40/41) for all Candida isolates;
one C. parapsilosis isolate had an MIC value of > 4 μg/ml.
Susceptibility to voriconazole was 90.2% (37/41). For C.
albicans, two isolates had MIC values > 4 μg/ml, and one
isolate had an MIC value between > 1 and 4 μg/ml. For C.
tropicalis, one isolate had an MIC > 4 μg/ml and another
isolate had an MIC value between > 1 and 4 μg/ml.
Treatment duration
Duration and dose by route of treatment is presented in
Table 2. The median duration of i.v. anidulafungin was
10.0 days (range, 1.0 to 37.0 days). Fourteen patients
stepped down to oral voriconazole therapy, with an overall
median duration of 10 days (range, 4.0 to 38.0 days).
Efficacy
The global response rate (clinical +microbiological response)
at EOT in the MITT population was 73.8% (95% CI,
58.0–86.1 [31/42 patients]) for the primary endpoint,
increasing to 79.4% (95% CI, 62.1–91.3 [27/34 patients])
in the per-protocol group (Table 3). Failure occurred in
11.9% of patients (5/42 patients) (Table 3). Secondary
endpoints included global response at EOIT, which was
78.6% (33/42 patients) (Table 4).
Clinical and microbiological responses for the MITT
analysis set were also summarized by baseline infection
pathogen susceptibility (data not shown). Clinical response
rates were slightly lower overall than microbiological
response rates. Clinical success was documented in
76.2% of patients, with microbiological success in 81%.
Only two patients (4.8%) experienced clinical failure,
with one patient (2.4%) having documented pathogen
persistence. Clinical assessment was indeterminate for
six patients (14.3%) (Table 3). Success rates for the MITT
group were 72.2% for C. tropicalis, the most common
pathogen identified in this study, and 71.4% for C. albicans
infection. Global success was achieved in 84.6% of patients
with previous surgery (11/13 patients), and 58.8% of
patients who were over 65 years old. In patients with a
central venous catheter, the successful global response
was 81.0% (17/21 patients) (Table 5).
In the MITT population, microbiological success was
80.0% (32/40) in patients with anidulafungin-susceptible
isolates and 81.1% (30/37) of those with voriconazole-
susceptible isolates; the respective proportions for clinical
success were 75.0% (30/40) and 75.7% (28/37). All patients
who had isolates resistant to either study agent achieved
both clinical and microbiological success. Clinical and
microbiological success was reported in all four infections
caused by C. parapsilosis.
There were no isolates that demonstrated an increase
in MICs during the course of the study, including those
from patients who were clinical failures where follow-up
data were available.
Patients with a successful clinical response had baseline
mean β-D-glucan (± SD) levels of 1095.8 ± 968.52 pg/ml,
compared to 1447.9 ± 2178.27 pg/ml for patients who
suffered clinical failure. At EOT, β-D-glucan levels were
1018.9 ± 783.76 pg/ml in patients who experienced
clinical success, and 2917.7 ± 4737.50 pg/ml in patients
with clinical failure.
Safety and tolerability profile
Twelve treatment-related AEs were reported in 10 patients
(Table 6). These included diarrhea and rash, both reported
in two patients, and the remaining eight treatment-
related AEs were each reported in a single patient
(chest discomfort, thirst, drug hypersensitivity, recurrence
of candidemia, hypokalemia, confusion, insomnia, and
choking). All treatment-related AEs were reported as
mild-to-moderate in severity.
The single treatment-related serious AE reported was
a recurrence of candidemia (as reported above) in a
54-year-old woman on Day 23, judged by the investigator
to be related to voriconazole treatment (after 14 days
of voriconazole treatment), which subsequently led to
discontinuation of therapy. This patient had C. glabrata
isolated at baseline, which was susceptible to both
voriconazole and anidulafungin (MIC value 0.5 μg/ml
for both study drugs). Two other patients also permanently
discontinued the study due to AEs (drug hypersensitivity
[n = 1] and skin rash [n = 1]), both considered by the
investigator to be related to anidulafungin treatment.
There were 10 deaths (23%) during the study, none
considered by the investigator to be related to candidemia
or to treatment with study drug. In addition, four patients
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died after completion of treatment, none considered by
the investigator to be related to study treatment.
Discussion
In this study, a regimen of i.v. anidulafungin was assessed
for the treatment of documented candidemia in adult Asian
patients. The study also included the option to step-down
therapy to oral voriconazole. Due to difficult and slow
enrollment, the overall sample size was small. However,
the efficacy and safety profile of anidulafungin was in line
with that previously observed in Western populations.
Efficacy results were generally consistent with those of
other studies, including the pivotal trial by Reboli et al.
that demonstrated better responses with anidulafungin
than fluconazole for the treatment of C/IC [12], and an
open-label study of anidulafungin dosed at 50 mg,





Enrollment Excluded  (n = 3)
Allocated to study








a confirmed documented 







population (n = 34)
Excluded from analysis
(n = 11)
Did not have a confirmed
documented diagnosis of
candidemia (n = 1)
Inclusion/exclusion criteria
violation (n = 2)
Did not receive at least 
5 days of i.v. anidulafungin 
(n = 4)
Study drug compliance
<75% or >120%, or other
study drug-related issues
(n = 4)
Discontinuations (n = 26)
Discontinued during active
treatment (n = 13)
Discontinued during
follow-up (n = 13)
Completed study (n = 17)
Patient died (n = 8)
Adverse events (n = 3)
Lack of efficacy (n = 2)
Patient died (n = 2)
Lost to follow-up (n = 6)
Subject no longer willing to
participate (n = 4)
Other (n = 1)
Analyzed for safety 
(n = 43)
Analyzed for laboratory
results (n = 40)
Figure 1 Patient flow chart.
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75 mg, and 100 mg, which reported global success
rates (both clinical and microbiological success, i.e.
cure/significant improvement of C/IC signs/symptoms
and eradication/presumed eradication of Candida spp.) of
84%, 90%, and 89%, respectively at EOT, and 72%, 85%,
and 83%, respectively, at follow-up [24]. This study suggests
that the treatment of candidemia with anidulafungin is as
effective in Asian populations as Western populations.
The crude mortality rate reported in this study (23%) was
Table 1 Patient baseline characteristics





Mean ± SD 56.5 (± 18.5)
Range 19–91






Mean ± SD 57.5 (± 12.2)
Range 32.0–84.0
Heightb, cm
Mean ± SD 162.4 (± 7.4)
Range 148.0–180.0
Baseline pathogenc, n (%)
Candida tropicalis 18 (41.9)
C. albicans 14 (32.6)
C. glabrata 6 (14.0)
C. parapsilosis 4 (9.3)
C. rugosa 1 (2.3)
No pathogen isolated 1 (2.3)
aData available from 41 patients.
bData available from 38 patients.
cPatients could have more than one pathogen isolated at baseline.
Abbreviation used: SD, standard deviation.
Table 2 Duration and dose by route of treatment;
ITT population
Parameter (n = 43)
Intravenous anidulafungin Oral voriconazole
Duration, daysa
n 43 14





Mean ± SD 117.8 (± 24.09) 364.8 (± 72.86)
Median 110.0 400.0
Range 102.7–200.0 193.8–400.0
aIncludes only days on which any dose was taken.
Abbreviations used: ITT, intent-to-treat; SD, standard deviation.
Table 3 Clinical, microbiological, and global responses at
the end of all treatment
Parameter MITT population PP population
Clinical response, % [n/N]
Success (95% CI) 76.2 (60.5–87.9) [32/42] 82.4 (65.5–93.2) [28/34]
Cure 64.3 [27/42] 67.6 [23/34]
Improvement 11.9 [5/42] 14.7 [5/34]
Failurea 4.8 [2/42] 5.9 [2/34]
Indeterminate 14.3 [6/42] 5.9 [2/34]
Not assessed 4.8 [2/42] 5.9 [2/34]
Microbiological response, % [n/N]
Success (95% CI) 81.0 (65.9–91.4) [34/42] 82.4 (65.5–93.2) [28/34]
Eradication 73.8 [31/42] 73.5 [25/34]
Presumed eradication 7.1 [3/42] 8.8 [3/34]
Failure 2.4 [1/42] 2.9 [1/34]
Not assessed 16.7 [7/42] 14.7 [5/34]
Global response, % [n/N]
Success (95% CI) 73.8 (58.0–86.1) [31/42] 79.4 (62.1–91.3) [27/34]
Failure 11.9 [5/42] 8.8 [3/34]
Not assessed 14.3 [6/42] 11.8 [4/34]
Abbreviations used: CI, confidence interval; MITT, modified intent-to-treat;
PP, per protocol.
Table 4 Clinical, microbiological, and global response
rates at various pre-defined efficacy timepoints













81.0 [34/42] 85.7 [36/42] 78.6 [33/42]
(65.9–91.4) (71.5–94.6) (63.2–89.7)
2 weeks after EOT 83.9 [26/31] 80.6 [25/31] 75.0 [24/32]
(66.3–94.5) (62.5–92.5) (56.6–88.5)




54.8 [17/31] 51.6 [16/31] 50.0 [16/32]
(36.0–72.7) (33.1–69.8) (31.9–68.1)
Abbreviations used: CI, confidence interval; EOT, end of all treatment; MITT,
modified intent-to-treat.
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also similar to that observed in anidulafungin-treated
candidemia patients in North America and Europe [12]
and in line with data reported for other echinocandins [8].
These rates are substantially lower than the crude mortality
(35% to 60%) associated with candidemia in Asian patients
who had not received echinocandins [2,4]. A more re-
cent prospective multicenter Phase IIIb trial (ICE study)
demonstrated that anidulafungin was effective and well
tolerated with a good safety profile for the treatment of
confirmed C/IC in critically ill patients from ≥ 1 of the
following subpopulations: post-abdominal surgery, solid
tumor, renal insufficiency, hepatic insufficiency, solid organ
transplant, neutropenia (neutrophil count < 500 cells/mm3),
and age ≥ 65 years. The global success rate (both clinical
and microbiological success) at EOT (69.5%) was similar
to that achieved when anidulafungin is administered in a
general population [13,14].
The causative strains isolated in the trial included
common Candida species found in Asia [2,6]. C. tropicalis
was the most commonly identified pathogen in this trial.
This species is not common in Europe and North
America, but data from our study in Asian patients
show that it was successfully treated with anidulafungin.
Successful responses against C. albicans, C. parapsilosis,
and C. glabrata infections were also documented, in line
with previous studies [2,6].
As may be expected, the combined rates of microbio-
logical eradication/presumed eradication were slightly
higher than the clinical success rates. Global success was
achieved in all patients who had baseline isolates resist-
ant to anidulafungin or voriconazole, possibly due to
catheter removal eliminating the source of infection.
Therefore, the success of treatment of resistant isolates
may not be counted as antifungal efficacy. There was no
evidence of the development of resistance during active
treatment, and there were no isolates that demonstrated
an increase in MICs during the course of the study.
Patients with successful clinical responses at EOT had
numerically lower mean β-D-glucan levels at baseline
than those patients who later experienced clinical failure.
This suggests the potential utility of this assay in determin-
ing the severity of infection and likely treatment prognosis,
and further studies are warranted.
Although investigators had the option to step-down to
oral voriconazole therapy after as few as 5 days of treatment
with anidulafungin, the median duration of anidulafungin
treatment was 11 days and only 14 patients were stepped-
down to oral therapy. The duration of i.v. treatment was
considerably longer than that reported in another short-
course trial (6 days) [25] and was only 3 days shorter
than reported in long-course therapy study (14 days)
[12]. Possible reasons for this apparent reluctance to
step-down to oral therapy at an early timepoint in this
study may include the high percentage of non-albicans
Table 5 Global response rates in all predefined patients






ANC≤ 500/mm3 50.0 [1/2] 1.3–98.7
ANC > 500/mm3 75.7 [28/37] 58.8–88.2
Baseline pathogensb
Candida albicans 71.4 [10/14] 41.9–91.6
C. glabrata 66.7 [4/6] 22.3–95.7
C. parapsilosis 100.0 [4/4] 39.8–100.0
C. rugosa 100.0 [1/1] 2.5–100.0
C. tropicalis 72.2 [13/18] 46.5–90.3
Previous surgeryc
Any surgery 84.6 [11/13] 54.6–98.1
Abdominal surgery 87.5 [7/8] 47.3–99.7
Organ transplantation
Kidney, liver, or heart 0.0 [0/0] Not applicable
Elderly status
Age≥ 65 years 58.8 [10/17] 32.9–81.6
Renal insufficiency
Creatinine clearance < 30 ml/min 54.5 [6/11] 23.4–83.3
Use of central venous catheterc
Yes 81.0 [17/21] 58.1–94.6
Receiving chemotherapyd
Yes 71.4 [5/7] 29.0–96.3
a Patients with a missing ANC were not included.
b A patient could have had more than one baseline pathogen.
c Up to 1 month before the baseline visit.
d Up to 3 months before the baseline visit.
Abbreviations used: ANC, absolute neutrophil count; CI, confidence interval;
MITT, modified intent-to-treat.
Table 6 Treatment-emergent adverse events
Anidulafungin n = 43
All-causality Treatment-related
Number of adverse events 150 12
Subjects with adverse events 35 9
Subjects with serious adverse events 16 1
Subjects with severe adverse events 13 0
Subjects discontinued due to
adverse events
3 3
Subjects with dose reduced or




All causality 10 (23.3)
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infections, the high proportion of critically ill post-
abdominal surgery patients (who may have remained
nil-by-mouth for a short period post-operation) and
slower clinical response due to an immunocompromised
state. It should be noted that during previous clinical
studies of anidulafungin for C/IC, patients could be
switched to oral fluconazole after completing the i.v.
treatment period with anidulafungin [12]. However,
due to the continuing increase in fluconazole-resistant
strains [1,6] and the high rate of fluconazole resistance
in some Asian countries [6], voriconazole only was
employed as oral step-down therapy in this study.
AEs were mostly mild or moderate, and consistent
with the known favorable safety profile of anidulafungin,
with no new safety concerns identified in this regional
population [12,26].
The slow enrollment rate in the study could have
occurred due to several reasons. The use of fluconazole
prophylaxis may have reduced the incidence of C/IC or led
to less detection by blood culture, and many candidemic
patients with APACHE II score between 20 and 25 were
excluded as per the protocol. Other potential shortfalls of
this study are the open-label design and the low number
of enrolled patients with azole-resistant Candida strains
(especially C. krusei).
Despite the small size, this study retains relevance to
clinical practice. First, anidulafungin is easy to use in the
clinic as it does not require dose adjustments for renal
and hepatic impairment or for concomitant drug use
[26-28]. This study included a number of patients who
may have required dose adjustment in this study if a
different echinocandin had been employed. Secondly,
because the study focused on patients with APACHE II
scores ≤ 20, the evaluation of clinical efficacy was less
likely to be confounded by the severity of the patient’s
illness. Finally, anidulafungin demonstrated an efficacy
and safety profile in Asian patients that was comparable
to clinical trials in Western populations.
Conclusions
Initial data are promising for a course of i.v. anidulafungin
for the treatment of C/IC in Asian patients. Although the
epidemiology of Candida infections was different in Asian
patients, the efficacy of anidulafungin was in line with
that previously observed in Western populations. Data
from the trial showed that treatment of C. tropicalis
was successful with i.v. anidulafungin. No new safety
concerns were identified.
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